3PBIOVIAN Adds Second 2,000 L Single-Use Bioreactor to Expand Mammalian Manufacturing Capacity

For biologics sponsors evaluating CDMO partnerships, 3PBIOVIAN has materially changed its capacity profile: the Spanish contract manufacturer has commissioned a second 2,000-liter single-use bioreactor for mammalian cell culture, bringing its GMP-ready scale range to 50 L through 2,000 L within a single integrated platform.

The addition extends a mammalian platform that already encompasses process development, analytical control, and batch release under one operational roof. For QA directors and technical transfer leads, the practical consequence is that a sponsor can move a recombinant protein program from early-stage development through routine commercial manufacturing without a site change, a continuity point that directly reduces scale-up risk and the associated revalidation burden.

The platform's architecture reflects an industrial-mindset approach to process design: manufacturing parameters are aligned with anticipated clinical and commercial requirements at early development stages, which compresses timeline exposure and limits late-stage process change notifications under 21 CFR Part 211 and comparable ICH Q10 frameworks. For regulatory affairs leads managing CMC packages, that upstream alignment carries downstream documentation benefits.

3PBIOVIAN has indicated that the bioreactor installation is one component of a broader capacity growth strategy, with further initiatives in the mammalian area and additional strategic areas expected in the months ahead. The company has not disclosed specific timelines or investment figures for those subsequent phases.

The competitive read for mid-size CDMOs is straightforward: single-use 2,000 L capacity at a site with integrated process development and batch release positions 3PBIOVIAN more directly against larger contract manufacturers that have historically held an advantage on scale alone.

How quickly the additional capacity is absorbed into active client programs will serve as the near-term indicator of whether the expansion meets the demand the company has cited as its rationale.

Source: 3PBIOVIAN via company press release, 27 May 2026.